Post-earnings recap
Reported
Thu, Apr 25, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report shows a slight miss on EPS, but the stock reacted positively, rising 2.45%. Investors may be encouraged by management's focus on innovation and future product pipelines. The lack of revenue data and guidance leaves some uncertainty, but the positive stock reaction suggests confidence in the company's long-term strategy.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | N/A | -1.23% |
Overall, management expressed confidence in their strategic direction despite missing EPS expectations. They emphasized their commitment to innovation.
Management highlighted ongoing investments in innovation.
They noted a strong pipeline of products expected to drive future growth.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—